Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

Menu

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
My View
Tags:
Europe International Approvals

Qdenga: Crunch Time For First Product In Parallel Review Route For EU And Non-EU Markets

  • News

Executive Summary

Takeda could soon learn whether the European Medicines Agency will recommend in favor of approving its dengue vaccine, which was reviewed under a new evaluation route that simultaneously targets EU and non-EU countries.

You may also be interested in...



Dengue Vaccine Qdenga & Nine Drugs Win EMA Thumbs Up

The European Medicines Agency has delivered its verdict on marketing applications for a raft of new medicines.

EU Moment of Truth For Abaloparatide & Advanced Therapy Tab-Cel

Radius’s abaloparatide, which was previously rejected by the European Medicine Agency, is among the latest products that are this week being considered for EU-wide marketing approval by the agency.

Mirum Awaits EMA Verdict On ‘Reprioritized’ Livmarli Filing

Mirum could soon find out if its decision to reprioritize its EU filings for its rare liver disease drug has paid off.

Table

View full table

Related Content

Pink Sheet

Topics

Related Companies

Tags:
Europe International Approvals
Latest Headlines

Is It Time To Promote US FDA’s Biosimilars Office Out Of OND?

Supplemental Filings: Califf Discusses Revolving Door; Poll Examines Public Trust In FDA Approvals

Recent And Upcoming FDA Advisory Committee Meetings

EMA Recommends Revoking EU Approval For Novartis’s Sickle Cell Disease Drug

See All
UsernamePublicRestriction

Register

PS147132

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By